{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:08:12Z","timestamp":1785391692560,"version":"3.55.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,22]]},"abstract":"<jats:p>\n                    Intravenous iron supplementation, particularly ferric carboxymaltose (FCM), has emerged as an effective therapeutic strategy for correcting iron deficiency (ID) in patients with heart failure with reduced ejection fraction (HFrEF). However, the enhancement related to the quality of life (QoL) and functional capacity remains unclear, specifically in the Vietnam population. This study assesses the enhancement of QoL and functional capacity in intravenous FCM therapy in heart failure patients with ID. We conducted a cross-sectional analysis study in patients with chronic HFrEF. Eligible patients diagnosed with ID were treated with FCM. Endpoint was the improvement in QoL, assessed by the European Quality of Life 5 Dimensions 5 Level Version questionnaire, and functional capacity, measured by the change in the 6-minute walk test and New York Heart Association Functional Classification. A total of 132 patients with chronic HFrEF, with 35.60% of patients with ID. The study population had a mean age of 65.7\u2005\u00b1\u20059.4 years, males accounted for 56.8%. Female, New York Heart Association \u22653 and poor QoL significantly associated with ID. Notably, 12 weeks after intervention, patients with poor QoL decreased from 48.9% to 34.0% (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). Functional capacity, assessed by the 6-minute walk test, improved with the median distance increasing from 239.90 (198.80\u2013291.70) m at baseline to 262.60 (219.50\u2013309.70) m (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.01). Nausea was reported by a small minority at 4.25%. Our study highlights the significant burden of ID in patients with HFrEF, emphasizing its strong association with symptom severity, functional impairment, and reduced QoL. Intravenous FCM therapy demonstrated significant improvements in iron parameters, functional capacity, and QoL, with a favorable safety profile.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000044060","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T21:02:34Z","timestamp":1756846954000},"page":"e44060","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Enhancing quality of life and functional capacity in heart failure patients with iron deficiency: A regional cross-sectional study on intravenous iron therapy in Vietnam"],"prefix":"10.1097","volume":"104","author":[{"given":"Quan Hong","family":"Doan","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An Viet","family":"Tran","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7227-2262","authenticated-orcid":false,"given":"Phuc Thi Hong","family":"Dinh","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh Duy","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Health Center of Phuoc Long District, Bac Lieu Province, Vietnam."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260430","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"R2-20260430","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure.","volume":"3","author":"Savarese","year":"2017","journal-title":"Card Fail Rev"},{"key":"R3-20260430","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"R4-20260430","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"R5-20260430","first-page":"33","article-title":"Serum iron deficiency in patients with chronic heart failure with reduced ejection fraction.","volume":"94","author":"Son","year":"2021","journal-title":"Vietnam J Cardiol"},{"key":"R6-20260430","doi-asserted-by":"crossref","first-page":"e027852","DOI":"10.1161\/JAHA.122.027852","article-title":"Burden, trends, and inequalities of heart failure globally, 1990 to 2019: a secondary analysis based on the Global Burden of Disease 2019 Study.","volume":"12","author":"Yan","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"R7-20260430","first-page":"e46","article-title":"Heart disease and stroke statistics--2010 update: a report from the American Heart Association.","volume":"121","author":"Lloyd-Jones","year":"2010","journal-title":"Circulation"},{"key":"R8-20260430","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jchf.2018.07.015","article-title":"Iron deficiency in heart failure: an overview.","volume":"7","author":"von Haehling","year":"2019","journal-title":"JACC Heart Fail"},{"key":"R9-20260430","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jchf.2017.08.023","article-title":"Anemia in heart failure: still relevant?","volume":"6","author":"Beverborg","year":"2018","journal-title":"JACC Heart Fail"},{"key":"R10-20260430","first-page":"4","article-title":"Iron deficiency in Russian heart failure patients.","volume":"62","author":"Mareev","year":"2022","journal-title":"Kardiologiia"},{"key":"R11-20260430","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ejhf.236","article-title":"Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?","volume":"17","author":"McDonagh","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"R12-20260430","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency.","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"R13-20260430","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"R14-20260430","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency.","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"issue":"Suppl I","key":"R15-20260430","doi-asserted-by":"crossref","first-page":"I96","DOI":"10.1093\/eurheartjsupp\/suac080","article-title":"Iron deficiency in heart failure: diagnosis and clinical implications.","volume":"24","author":"Del Pinto","year":"2022","journal-title":"Eur Heart J Suppl"},{"key":"R16-20260430","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/ejhf.2338","article-title":"Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry.","volume":"23","author":"Becher","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"R17-20260430","first-page":"1449","article-title":"A prospective study on characterization of iron deficiency in patients with chronic heart failure.","volume":"31","author":"Riaz","year":"2024","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"R18-20260430","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.mjafi.2022.04.013","article-title":"Iron deficiency in patients of heart failure with reduced ejection fraction.","volume":"78","author":"Singh","year":"2022","journal-title":"Med J Armed Forces India"},{"key":"R19-20260430","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jacc.2017.12.027","article-title":"The burden of iron deficiency in heart failure: therapeutic approach.","volume":"71","author":"Rocha","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R20-20260430","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00277-020-04338-2","article-title":"Correction of iron deficiency in hospitalized heart failure patients does not improve patient outcomes.","volume":"100","author":"Mistry","year":"2021","journal-title":"Ann Hematol"},{"key":"R21-20260430","doi-asserted-by":"crossref","first-page":"3","DOI":"10.18087\/cardio.2023.9.n2413","article-title":"Female and male phenotypes of iron deficiency in CHF.","volume":"63","author":"Begrambekova","year":"2023","journal-title":"Kardiologiia"},{"key":"R22-20260430","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jacc.2021.11.039","article-title":"Criteria for iron deficiency in patients with heart failure.","volume":"79","author":"Masini","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R23-20260430","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.3346\/jkms.2023.38.e177","article-title":"Iron deficiency in heart failure patients in Korea: insights from the KorHF Registry.","volume":"38","author":"Park","year":"2023","journal-title":"J Korean Med Sci"},{"key":"R24-20260430","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijcard.2014.03.169","article-title":"Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study.","volume":"174","author":"Enjuanes","year":"2013","journal-title":"Int J Cardiol"},{"key":"R25-20260430","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1007\/s00277-019-03777-w","article-title":"Iron deficiency in heart failure, an underdiagnosed and undertreated condition during hospitalization.","volume":"98","author":"Mistry","year":"2019","journal-title":"Ann Hematol"},{"key":"R26-20260430","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/eurheartj\/ehae093","article-title":"Intravenous iron, only for those in need.","volume":"45","author":"van der Meer","year":"2024","journal-title":"Eur Heart J"},{"key":"R27-20260430","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1093\/eurheartj\/ehab234","article-title":"The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.","volume":"42","author":"Jankowska","year":"2021","journal-title":"Eur Heart J"},{"key":"R28-20260430","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa2304968","article-title":"Ferric carboxymaltose in heart failure with iron deficiency.","volume":"389","author":"Mentz","year":"2023","journal-title":"N Engl J Med"},{"key":"R29-20260430","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.3889\/oamjms.2022.10897","article-title":"The role of neutrophil gelatinase-associated lipocalin and N-terminal pro B-type natriuretic peptide in the prediction of heart failure in patients with acute coronary syndrome.","volume":"10","author":"Tran","year":"2022","journal-title":"Open Access Maced J Med Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:00:17Z","timestamp":1777590017000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":29,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044060","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}